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1 Background and problem statement 
The valuation and pricing of health technologies differs from the 
traditional goods and services which are defined within an environment of 
classic market mechanisms. From the economical perspective, goods and 
services are valued at a price that is considered to be acceptable for the 
consumers. Therefore, the price of these goods and services is defined by the 
supply and the demand on the market. Due to market failures the valuation of 
innovative pharmaceuticals is a more complex issue. The process of defining 
the value and the price of innovative pharmaceuticals differs mainly due to 
the patent protection that creates a monopoly status, the high cost of 
innovation and the third party payer (e.g. national insurance fund) that has a 
prominent role in the market transactions. The actual price of these products 
is defined through a negotiation between the pharmaceutical manufacturer 
(the seller) and a third party payer (the buyer). This process is supported by 
the different tools of health economics. Despite the fact that this field of 
science is relatively new, several methods had been developed with the aim 
of setting the prices of health technologies (Neumann et al., 2018). 
A frequently followed concept of health economics in case of 
innovative technologies is the value based pricing approach (Drummond et 
al., 2015). The following question is raised: What is the value of a new 
pharmaceutical product or other health technology? According to the 
principles of health economics the value is defined based on the incremental 
health gain associated with the new health technology compared to the 
current standard of care. The health gain is defined by the combination of 
improved quality of life and/or the life years gained and by the cost of the 
medical incidents avoided during the application (Drummond et al., 2015). 
This concept has become widely used in developed countries mainly because 
the data and information required for such evaluation are available in many 
cases.  
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Lately, the focus of pharmaceutical innovation has changed, which 
also created new challenges in the assessment of the value as well. Several 
pharmaceutical manufacturers started to focus on those niche markets where 
the unmet medical need is higher. One prominent example for this is the field 
of rare diseases.  
The rare diseases relate to a highly heterogenic patient population. 
These diseases are classified only by their prevalence in the population and 
by their severity. There is no universally accepted definition. Different 
regions, countries and organizations have different cut-off points for the rarity 
to include a disease to the group of rare diseases (Richter et al., 2015).  
As a result of the low number of patients the research and 
development, the authorization of the procedures for diagnosing rare diseases 
and the pharmaceuticals to treat diagnosed patients have relatively higher 
costs. Therefore, in a traditional regulatory environment there was a high risk 
of poor return on investment for such goods and services. For these reasons 
the pharmaceutical industry was not focusing on the market of rare diseases 
in the past. The term “orphan medicinal products” is generally used for the 
technologies applied for the diagnosis, prevention and treatment of rare 
diseases. The pharmaceuticals used for the treatment of rare diseases are 
called “orphan drugs” (European Commission, 2018). The term „orphan” 
refers to this neglected and abandoned status of patients on this field. The 
traditional market authorization and pricing and reimbursement procedures 
did not foster the pharmaceutical innovation in this field. The three 
underlying reasons were: 1) it is not realistic to conduct a randomized clinical 
trial with the traditionally required large number of patients, 2) the low 
number of patients leads to a high risk of poor return on investment and 3) if 
the prices set higher to decrease the risk of poor return on investment, the 
third party payer might cannot afford to reimburse the pharmaceuticals.  
Due to the highlighted reasons incentives were introduced for the 
research and development of orphan drugs, mainly in the developed 
countries. These incentives were first provided in the United States in 1983 
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and then in 1991 in Singapore, in 1993 in Japan, in 1997 in Australia and in 
2000 in the European Union (Orphanet, 2018a).  
According to the European Union, those products can be labelled as 
orphan drugs, which meet a number of criteria: 1) it must be intended for the 
treatment, prevention or diagnosis of a disease that is life-threatening or 
chronically debilitating; 2) the prevalence of the condition in the EU must not 
be more than 5 in 10,000 or it must be unlikely that marketing of the medicine 
would generate sufficient returns to justify the investment needed for its 
development; 3) there is no satisfactory method of diagnosis, prevention or 
treatment of the condition concerned can be authorized, or, if such a method 
exists, the medicine must be of significant benefit to those affected by the 
condition. 
There are a number of reasons why there are more and more 
treatment options for rare diseases such as the changing regulatory 
environment, incentives for the industry, easier authorization process, 
changing industrial strategies and scientific development. Still the process of 
defining the value and the price of these products is very challenging. 
Currently those health technology assessment frameworks which are 
traditionally used for pricing and reimbursement decisions might not be able 
to appropriately define the value of an orphan drug. Several times positive 
reimbursement decisions are being made also in case of those drugs where 
only limited evidence is available on efficacy, safety or cost-effectiveness. In 
terms of budget impact, the financial burden on the payer might be acceptable 
due to the low number of patients, but the treatment costs per patient could 
be extremely high. Nowadays the budget impact for all orphan drugs is 
becoming higher, however, the actual impact on the health system is less 
known due to the different financing mechanisms. The concept of equity 
appears to be an important criterion in theory, but the explicit definition of 
how to consider equity in decision is not defined appropriately.  
Due to these reasons, the health technology assessment of orphan 
drugs needs further and more in-depth investigation. When the evaluation of 
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these technologies is not possible with the traditional framework, then the 
applied criteria and tools should be re-structured and re-defined and if 
necessary, new aspects should be defined for the evaluation.  
The objective of this research is to explore the applicability of the 
current health technology assessment frameworks in case of orphan drugs and 
to reveal the potential constrains of their application. This research attempts 
to provide recommendations to re-structure or re-consider existing criteria 
that may lead to improve the transparency and the consistency of decision 
making. Furthermore, the research attempts to introduce new criteria, which 
could be used in the current framework for the assessment of the health 
technologies. Ultimately the objective of this research is to improve the 
assessment of orphan drugs with a special attention to the Hungarian context 
in order to strengthen the evidence base of decisions on the public resources.  
2 Applied methodology 
The dissertation was based on four independent researches carried 
out during the doctoral program.  
2.1 Systematic literature review to investigate the disease 
prevalence of Sanfilippo syndrome 
To investigate the methodology of studies relevant to the clinical 
burden of rare diseases a systematic literature review was conducted on a 
selected rare disease. The study focused on epidemiological studies. The 
selected disease was the Sanfilippo syndrome. The primary objective of the 
study was to review the applied methodologies of the epidemiological studies 
in a disease where national registries are not available and where neonatal 
screening tests are not widely applied. Based on the identified studies we also 
defined the prevalence of the disease in different regions of the world (Zelei 
et al., 2018). 
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The systematic literature review was conducted and reported in 
compliance with the internationally accepted PRISMA guideline (Liberati et 
al., 2009, Moher et al., 2009). In the first step, structured searches were 
conducted in the following databases: Medline, Embase, Cochrane Database 
of Systematic Reviews, Academic Search Complete, CINAHL, CRD 
Database. In addition, the databases and websites of relevant rare disease 
organizations were reviewed to identify additional studies. The title and 
abstract screening of the hits was conducted by two independent researchers. 
The full text version of the potentially relevant papers was reviewed by one 
researcher. Based on the full text review the final pool of relevant articles was 
defined. Articles without relevant data were excluded. From the included 
studies the relevant data was extracted to a pre-defined structured Microsoft 
Excel spreadsheet. Qualitative synthesis of the research findings was 
performed, as quantitative synthesis (meta-analysis) of the collected disease 
prevalence data did not promise substantial added value. 
2.2 Systematic literature review on the evaluation criteria of 
orphan medicines  
This study attempted to systematically collect those evaluation 
criteria which are relevant for the treatments of rare diseases in case of a 
health technology assessment process. In the past, no comprehensive study 
was conducted in Central and Eastern Europe that investigated the standard 
HTA framework and considered additional criteria for the assessment of 
orphan drugs. The primary objective of the study was to provide a well-
established guidance for the fine-tuning and re-considering the traditional 
framework of the health technology assessment, according to the specific 
characteristics of the rare diseases. The search was conducted globally, but 
special attention was given to the Central and Eastern European region, to 
draw conclusions that are more relevant to the Hungarian context. Formerly, 
such focus on this region was a gap in the literature.  
The systematic literature review was conducted and reported in 
compliance with the internationally accepted PRIMA guideline (Liberati et 
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al., 2009, Moher et al., 2009). In the first step, structured searches were 
conducted with PubMed and Scopus search engines. The title and abstract 
screening of the hits from different databases was conducted by two 
independent researchers. The full text version of the potentially relevant 
papers was reviewed in the next steps. Based on the full text review, the final 
pool of relevant articles was defined. Articles without relevant data were 
excluded. From the included studies the relevant data were extracted to a pre-
defined structured Microsoft Excel spreadsheet. The relevant information 
were collected according to the different major categories of the traditional 
health technology assessment: efficacy, effectiveness, cost-effectiveness, 
budget impact and equity. Every potential information for each criterion was 
collected including the usefulness of the criteria, its limitation and its 
potential further improvement. Furthermore, any additional criteria that could 
not be categorized to the abovementioned criteria were collected separately. 
The study eventually collected and comprehensively described all potential 
value drives that could be used in case of rare diseases. Qualitative synthesis 
of the findings was performed as the nature of the information collected did 
not allow for quantitative synthesis or further meta-analysis. 
2.3 Data request from the National Health Insurance Fund of 
Hungary to estimate the budget impact of orphan drugs  
Since there is a limited evidence on the budget impact of orphan 
drugs a data request was submitted to the National Health Insurance Fund of 
Hungary that is responsible for allocating the public resources for the 
pharmaceutical products.  
In the first step, the list of orphan drugs was defined which had 
marketing authorization in the European Union. The Orphanet website was 
used for this purpose, and 83 orphan drugs were identified. This list was 
double-checked on the website of the European Medicines Agency.  
One objective of the data request was to define how many of the 83 
orphan drugs are available in Hungary. We considered those drugs available 
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which were reimbursed from public resources to the patients. The second 
objective was to define the cumulative budget impact of those orphan drugs 
that are publicly reimbursed. The budget impact was defined in accordance 
with the expenditure of the National Health Insurance Fund in 2013 and 2014. 
We considered all form of reimbursements such as standard reimbursement 
through retail pharmacies or hospitals and special patient level 
reimbursement based on individual requests. 
The number of available drugs were compared to data available 
from other countries published in the literature. The cumulative budget 
impact of orphan drugs was compared to the total expenditure on 
pharmaceuticals and to the total healthcare expenditure in Hungary. The 
expenditure on pharmaceuticals and the total healthcare expenditure was 
defined from the data published by the Hungarian Central Statistical Office. 
The percentage of orphan drugs available was compared to data available 
from other countries. Eventually, the study defined the financial burden of 
orphan drugs from the perspective of the public payer.  
2.4 The methodology of investigating the association between 
the incremental cost-effectiveness ratio, the disease 
prevalence and the incremental health gain of orphan 
drugs 
To assess the cost-effectiveness of orphan drugs, we selected the 
United Kingdom as a benchmark, since they have been using explicit cost-
effectiveness thresholds for a long time and have made the analyses public. 
Therefore, these are freely available, researchable, and easy to be analysed. 
In our study, we investigated that how many orphan drugs are cost-effective 
at the standard threshold, and whether there is a correlation between the 
prevalence of the disease being treated and the incremental cost-effectiveness 
ratio (ICER). 
In the database of Orphanet we identified 84 orphan drugs with 
marketing authorization rights in 2015 December. Publicly available cost-
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utility analyses from the United Kingdom were searched. The sources 
included the reports of relevant public institutes: National Health Service, 
National Institute for Health and Care Excellence (NICE), Scottish Medicines 
Consortium (SMC), CRD/CHE Technology Assessment Group of University 
of York and scientific publications. In addition, we performed Google 
searches to identify further relevant analyses.  
The identified reports were downloaded in full text. Data was 
extracted to a structured Microsoft Excel spreadsheet. ICER values and 
incremental QALY gains were systematically collected for all orphan drugs 
from the identified assessment reports. Additionally, the collected data 
included the source of data, year of publication, indication, applied 
comparator therapy, timeline of the analysis and applied sensitivity analysis. 
In every analysis we considered the base case as the relevant scenario.  
Point prevalence estimations of the target diseases were obtained 
from Orphanet prevalence report (Orphanet, 2018b). 
In the first step, ICER values were plotted against the disease 
prevalence. The association of the two variables were tested. We applied the 
least squares method to fit a curve and we investigated the coefficient of 
determination (R2). In the second step, ICER values were plotted against the 
incremental health gains and the disease prevalences were symbolized by the 
size of the data points. The hypothesis was that higher incremental QALY 
gains and/or lower disease prevalence is associated with higher ICERs. This 
hypothesis was tested with an index calculated according to the following 
equation:  
Pricing index =
"incremental QALY gain per patient"
"disease prevalence” x  "ICER"
 
 
The selected orphan drugs were compared according to this index. 
Based on the relative values the following categories were defined: 1) 
Overpriced, 2) Fair priced, 3) Under priced. In scenario analysis the large 
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scale difference in disease prevalence values was attenuated by logarithmic 
transformation and its influence on the results was investigated. Since this 
method is not generally applied, the limitation of the method is that only the 
included drugs can be compared to each other, the price is judged relatively 
for the current sample.  
3 Results 
3.1 Measuring disease prevalence 
 The prevalence of Sanfilippo syndrome was measured with different 
methods. These methods were different in terms of the terminology 
but also in terms of the calculation method, therefore the 
interpretation and the comparability of the results is limited. The 
major conclusion of the research is that in case of rare diseases the 
methodology of the relevant studies should undergo a critical review.  
 From the study designs and related calculation methods of the 
epidemiological measures identified during the systematic literature 
review on the epidemiology of Sanfilippo syndrome, the Dx method 
used to estimate lifetime risk at birth can be proposed, 
 furthermore, if we can apply sufficiently long follow-up period to 
make sure that the disease can appear in all individuals included in 
the study, then the cumulative incidence measured in the birth cohort 
also provides reliable result. This is especially true in those cases 
where the disease manifests right after birth. 
 According to the results of studies identified by the systematic 
literature review, in each birth cohort from 100 000 people only a few 
will be diagnosed with the Sanfilippo syndrome during their life. If 
the life expectancy of patients is below the life expectancy of the 
general population (which has also been proven), the point 
prevalence of the disease at any given point in time cannot exceed 
the reported values. Therefore, the results undoubtedly prove that 
Sanfilippo syndrome is a rare disease, i.e. in Europe it affects less 
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than five people out of 10,000 people. In addition, the analysis 
provided information on the frequency and distribution of the four 
subtypes (A-D), A and B were more prevalent depending on the area, 
while subtype C and D are extremely rare in all studied regions. 
 In the absence of reliable statistics such as national or international 
patient registries or screening databases, the systematic literature 
review is an appropriate tool for estimating the prevalence of a rare 
disease. Systematic collection and evaluation of information 
accumulated in scientific literature can provide evidence both in 
national and international comparison. 
3.2 Measuring disease progression 
 There was very little data available in the literature regarding the 
progression of Sanfilippo syndrome. 
 The identified clinical parameters are difficult to use as surrogate 
endpoints, and their relationship with hard endpoints (e.g. survival) 
can be inaccurately estimated. 
 Information on the hard disease progression measures is incomplete, 
limited number of studies published relevant data. Subtypes A and B 
appear in early childhood (3-5 years of age) and patients have very 
poor life expectancy (~ 15 years). Subtypes C and D occur somewhat 
later (5-10 years of age) and patients' life expectancy is also slightly 
longer. On patient survival, as a hard endpoint, few good quality data 
was available, furthermore we should apply too long follow up period 
to make it measurable, and so it cannot be used as a clinical trial 
endpoint. 
 Based on these results, the primary role of hard endpoints in case of 
rare diseases can be rarely expected, instead, a composite endpoint 
including most severe symptoms that describes well the progression 
of the disease may be suggested as a clinical trial endpoint. 
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3.3 Budget impact of orphan drugs  
 Based on the international literature and the results of data request in 
Hungary, it can be concluded that countries spend a significant 
proportion of their pharmaceutical budget on orphan drugs, 
especially since this spending refers to a very small number of 
patients. 
 According to the literature data, the drug group places an increasing 
burden on public payers. Central and Eastern European countries 
reported access barriers. 
 A few drugs produce a large part of the cumulative budget impact, 
for which budget impact analysis should receive a special attention. 
 Sophisticated budget impact analysis is required for all orphan drugs, 
but especially for those with multiple indications or potential for off-
label use. When new indications are introduced, new budget impact 
analysis is required. 
 The Hungarian data are like the literature data, they are comparable 
both in their extent and in their increasing tendency. In Hungary, the 
share of orphan drugs in the public pharmaceutical budget was 3.15% 
in 2013 and 3.94% in 2014. There was some lagging behind the 
western countries in the number and proportion of medicines being 
reimbursed. 
 Overall, it can be concluded that the reimbursement of orphan drugs 
is now a major burden on public payers, consequently, the 
reimbursement of certain drugs because of limited budget impact can 
no longer be maintained. 
3.4 Cost-effectiveness of orphan drugs 
 The results of the systematic literature review and the data collection 
in the United Kingdom have shown that certain orphan drugs can 
meet the standard cost-effectiveness criteria, as out of 31 drugs, 9 had 
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ICER below the threshold. Therefore, the uniform elevation of the 
cost-effectiveness threshold does not seem to be justified. 
 Consideration may be given to establish an increasing threshold with 
decreasing disease prevalence, as drugs with exceptionally high 
ICERs typically belonged to ultra rare diseases. 
 Social preference (i.e. willingness to pay) must be priced for rare 
diseases, because in many cases the reimbursement occurs along 
ICERs that are significantly higher than traditionally accepted 
thresholds. It should be emphasized that assessing willingness to pay 
is important, on the one hand, because of this we can make fair 
reimbursement decisions, and on the other hand it encourages 
manufacturers to develop more effective orphan drugs, furthermore, 
it creates a transparent and predictable regulatory environment. 
3.5 The relationship of disease prevalence and incremental 
health gains with the cost-effectiveness ratio 
 The role of target disease prevalence and the role of incremental 
health gains provided by the new drug in pricing of orphan drugs 
cannot be justified. In the investigated drug group, ICER values (past 
pricing decisions) were basically influenced by other factors. 
 The results of our research have shown that the ICER values of 
orphan drugs can be compared and evaluated with a simple index 
calculation methodology in respect of the two studied parameters. 
Since previous studies did not investigate the relationship between 
these parameters, there is no reference point available, and the 
comparisons could only be made relative to each other. Although the 
relationship could not be established, these two parameters may play 
a role in the evaluation of orphan drugs in the future. 
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3.6 Equity aspects 
 Our research confirmed that equity arguments play an extremely 
important role in determining the value of orphan drugs. 
 Based on the systematic literature review it can be stated that there is 
no uniform equity concept, several theories play role in supporting 
the equity arguments. The analysis provided an opportunity to 
organize and interpret the equity theories, but deeper analysis of these 
and presentation of empirical evidence has not been occurred so far. 
 There is no detailed recommendation in the literature to establish the 
measurability of the equity aspect and its practical application in the 
framework of health technology assessment. 
 On a theoretical basis, the prevalence of the disease is related to 
equity arguments, so this variable can be considered when the equity 
aspect is evaluated. 
 On the basis of equity, the severity/life-threatening nature of the 
disease or the availability of treatment alternatives can also be 
assessed. 
3.7 Additional evaluation criteria  
 The results of the research have highlighted the need to integrate 
several criteria in the evaluation process that have been examined so 
far inadequately or with inappropriate weight. 
 In connection with the disease, consideration should be given to its 
severity / life-threatening nature and the existence of other treatments 
in the disease area. In connection with the new therapy, consideration 
should be given to the nature of the therapeutic effect (reversing or 
only slowing the progression), the degree of scientific research and 
development, innovation and production complexity associated with 
the new product. 
 However, in most cases, there are no arguments based on strong 
evidence to support the additional aspects. As a result, the practical 
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application of these criteria during health technology assessment is 
also limited. 
 In addition, the relationship of additional aspects with existing 
technology assessment criteria has not been investigated adequately, 
i.e. whether a value-bearing factor is considered multiple times or not 
(e.g. quality of life that is taken into account in cost-effectiveness 
calculations and severity of disease as an additional aspect). 
3.8 Recommendations for developing technology assessment 
framework 
The standard framework of health technology assessment has 
limitations in the case of therapies for rare diseases, so the revision of 
previously established frameworks has become necessary. With my results, I 
have sought a deeper understanding and analysis of the classical aspects and 
I tried to recommend the inclusion of additional criteria in the evaluation 
process. 
The prevalence of the target disease is not investigated by the 
standard technology assessment criteria, because in the case of traditional 
diseases this aspect is not considered as a value bearing factor. Currently, in 
the field of rare diseases, the investigation of the disease prevalence is 
primarily necessary to obtain the orphan designation. At the same time, it can 
be assumed that the prevalence of the disease is also related to the equity 
aspects in addition to the burden of disease and the budget impact. Therefore, 
I recommend taking into account the prevalence of the target disease when 
evaluating the drugs for rare diseases, i.e. the rarer the disease, the higher the 
premium for a particular treatment for the disease. If we accept this and the 
equity aspects continue to have significant weight during the evaluation of 
orphan drugs, then the reliability of the potentially related disease prevalence 
data will come to the fore, and the methodological recommendations for their 
estimation methods will be more appreciated. 
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Using the logic applied by Paulden et al. (2015) as a starting point, 
based on my results the factors listed in Table 1 can be considered during the 
health technology assessment of treatments of rare diseases. 
Table 1. Factors to consider in the health technology assessment of 
treatments of rare diseases  
Disease-
related 
factors 
 Prevalence of the disease 
 severity/life-threatening nature of the disease  
 availability of treatment alternatives 
 identifiability of responders to treatment / heterogeneity 
of disease (existence of potential subgroups)  
Treatment-
related 
factors 
 evidence of treatment efficacy or effectiveness 
 safety profile of treatment 
 nature of the therapeutic effect (reversing, stabilizing or 
only slowing the progression) / magnitude of treatment 
benefit   
 „bridge” therapy: the procedure allows patients to reach 
definitive treatment (e.g. transplantation)  
 innovative profile of treatment 
 manufacturing complexity 
Economic 
factors 
 cost-effectiveness of treatment (without mandatory 
threshold)  
 budget impact 
 number of indications 
 potential for off-label use 
Social 
factors 
 societal impact of treatment (i.e., indirect costs on 
families and caregivers) 
 equity in access to treatment 
 opportunity cost of treatment/ effect on distribution of 
health within the society 
 
There are two ways to apply the listed criteria. The first is to create 
a multi-criteria decision analysis (MCDA) tool, in which a therapy is 
evaluated based on several explicit criteria (i.e. scoring), and then the scores 
of each criterion are weighted according to a predefined algorithm. Based on 
the aggregate score it is possible to decide whether a therapy is preferable 
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compared to other therapies or it is acceptable based on a pre-defined 
threshold. (Friedmann et al., 2018, Kolasa et al., 2018, Schey et al., 2017). 
Another possible way is to determine the size of price premium we consider 
realistic for the increasing values of each criterion. (Hall and Sireau, 2013). 
For example, a "price premium" can be determined which increases by 
disease prevalence bands or continuously and raises the acceptable price of 
the drug compared to the price set at the standard threshold, namely in case 
of rarer diseases higher price premium can be applied. Such monetary value 
is currently used only for incremental health gains. With different logic, both 
methods are suitable for considering additional aspects. Experience with the 
MCDA is more widely available, so this framework using the criteria above 
can be proposed as an appropriate method in the evaluation of health 
technologies used in the treatment of rare diseases. 
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